Pipeline– tag –
-
Harrison Zhang et al. Unveil ‘Virtual Biotech’: Multi-Agent AI System to Transform Drug Discovery Decision-Making
EurekAlert! USA Overview Harrison Zhang and colleagues have introduced 'Virtual Biotech,' a novel multi-agent AI system designed to enhance drug discovery decision-making. This platform coordinates specialized AI 'scientist' agents under... -
Stanford University Develops ‘Virtual Biotech’ with 37,000 AI Agents for Drug Discovery, Published in Science
Science (via Chosunilbo DB) USA Overview A Stanford University research team has developed 'Virtual Biotech,' a system where up to 37,000 AI agents collaborate on drug discovery, with findings published in the journal Science. This syste... -
Synaptics Launches Torq Edge AI Platform Featuring Google’s RISC-V Coral Open NPU, Boosting Multimodal Inference for Embedded IoT
Edge AI and Vision Insights USA Overview Synaptics unveiled its "Torq™ Edge AI platform," a high-performance, low-power Neural Processing Unit (NPU) subsystem for edge AI, integrated with Google's RISC-V based Coral Open NPU. Part of the... -
AI-Discovered Drugs Advance: Insilico Medicine’s Rentosertib Enters Phase III, But Fully AI-Designed Drugs Await Approval (As of 2026)
Life Science Daily News Global Overview As of 2026, AI-generated pharmaceuticals are rapidly advancing through clinical development, with Insilico Medicine's Rentosertib reaching Phase III trials—a significant milestone for AI drug disco... -
Amgen Terminates $500M+ Collaboration with TScan, TScan CEO Affirms No Impact on Core Strategy
Fierce Biotech USA Overview Amgen has scrapped its over $500 million collaboration with TScan Therapeutics focused on immune cell therapy development. Despite this, TScan's CEO asserted that the termination would not affect the company's... -
CrystalO Biopharma Signs Collaboration and Licensing Deal with Almirall for AI-Driven Skin Disease Drug Discovery, Valued Up to €254.5 Million
Insight, China's Pharmaceutical Industry China Overview CrystalO Biopharma has signed a collaboration and licensing agreement with Almirall, a global biopharmaceutical company, to develop innovative drug candidates for skin diseases. The... -
Pathos AI and AstraZeneca Partner to Advance ER+/HER2- Breast Cancer Therapy AZD4241 Using AI-Driven Platform
Fierce Biotech USA Overview Clinical-stage AI company Pathos AI has partnered with AstraZeneca in a co-exclusive licensing agreement to advance AZD4241, an investigational therapy for ER+/HER2- breast cancer. Pathos will lead the early c... -
SpaceX to Finalize $60 Billion All-Stock Acquisition of AI Coding Assistant Developer Anysphere
SatNews USA Overview SpaceX is nearing the finalization of its $60 billion all-stock acquisition of Anysphere, the company behind the AI-powered coding assistant Cursor. This strategic move aims to significantly expand SpaceX's internal ... -
SpaceX/xAI Acquires AI Coding Platform Cursor Amidst $600 Billion Pending M&A Deals
DealRoom.net USA Overview As of August 2026, approximately 20 M&A deals valued at $600 billion are pending completion. Notably, SpaceX acquired AI coding platform Cursor, to be integrated into xAI's computing and model stack, which S... -
BlossomHill and Latigo Secure $496 Million in Combined IPOs, Fueling Clinical-Stage Cancer and Non-Opioid Pain Therapies
Endpoints News USA Overview BlossomHill Therapeutics and Latigo Biotherapeutics successfully completed their IPOs, raising a combined total of $496 million, with $150 million for BlossomHill and $346 million for Latigo. These substantial...
